Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis
| Autor: | Reinilde Heyrman, Suzanne Oparil, James Lee, Eli M. Roth, Victor Fernandez, Michael Melino |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Urology Diastole Tetrazoles Subgroup analysis Blood Pressure Body Mass Index Hydrochlorothiazide Double-Blind Method Internal medicine Internal Medicine medicine Prevalence Humans Amlodipine Obesity Antihypertensive Agents Aged Olmesartan Medoxomil business.industry Imidazoles Middle Aged medicine.disease Original Papers Endocrinology Blood pressure Treatment Outcome Hypertension Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business Olmesartan Body mass index medicine.drug |
| Zdroj: | Journal of Clinical Hypertension (Greenwich, Conn.) |
| ISSN: | 1751-7176 1524-6175 |
| Popis: | The objective of this prespecified TRINITY study subgroup analysis was to assess the efficacy and safety of triple-combination treatment with olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg vs the component dual-combination treatments in obese (body mass index [BMI] ≥30 kg/m(2) ) and nonobese (BMI30 kg/m(2) ) hypertensive participants. The double-blind treatment period primary end point was the least-squares (LS) mean reduction in seated diastolic BP (SeDBP) at week 12 (end of the double-blind period). Of the 2492 randomized participants, 1555 (62.4%) had BMI ≥30 kg/m(2) . Irrespective of BMI, triple-combination treatment resulted in greater LS mean reductions in seated BP (SeBP) (≥30 kg/m(2) , 6.7-10.5/4.5-7.3 mm Hg;30 kg/m(2) , 5.1-8.6/2.5-6.0 mm Hg [P.005] vs dual-combination treatments for both subgroups) at week 12. Furthermore, triple-combination treatment enabled a greater proportion of participants to reach BP goal vs the dual-combination treatments (≥30 kg/m(2) , 62% vs 31%-46% [P.0001];30 kg/m(2) , 69% vs 41%-55% [P.005]) at week 12. SeBP reduction and goal attainment (≥30 kg/m(2) , 63%;30 kg/m(2) , 67%) was maintained through week 52/early termination. Triple-combination treatment was well tolerated in both BMI subgroups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|